Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway
Hassan, M., Balah, A., Abdelbaky, N. (2021). Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway. EKB Journal Management System, 1(2), 72-87. doi: 10.21608/aijpms.2021.66347.1052
Mariam Hassan; Amany Balah; Nayira A. Abdelbaky. "Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway". EKB Journal Management System, 1, 2, 2021, 72-87. doi: 10.21608/aijpms.2021.66347.1052
Hassan, M., Balah, A., Abdelbaky, N. (2021). 'Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway', EKB Journal Management System, 1(2), pp. 72-87. doi: 10.21608/aijpms.2021.66347.1052
Hassan, M., Balah, A., Abdelbaky, N. Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway. EKB Journal Management System, 2021; 1(2): 72-87. doi: 10.21608/aijpms.2021.66347.1052

Aliskiren and L-carnitine attenuate isoproterenol-induced cardiac hypertrophy via targeting IL-6/JAK2/STAT3/SOCS3 signaling pathway

Azhar International Journal of Pharmaceutical and Medical Sciences
Article 9, Volume 1, Issue 2, June 2021, Page 72-87  XML PDF (2.03 MB)
Document Type: Original research articles
DOI: 10.21608/aijpms.2021.66347.1052
View on SCiNiTO View on SCiNiTO
Authors
Mariam Hassan1; Amany Balah2; Nayira A. Abdelbaky email orcid 3
1Egyptian Ministry of Health and Population, Cairo, Egypt.
2Pharmacology Department, Faculty of Pharmacy, Al-Azhar University, Cairo, Egypt
3Faculty of Pharmacy, Al-Azhar University
Abstract
This research was designed to assess the inhibitory action of aliskiren, L-carnitine, and their combined treatment on JAK2/STAT3/SOCS3 signaling pathway in cardiac hypertrophy induced by isoproterenol injection in rats. Wistar rats were injected with isoproterenol (5 mg/kg/day) for 15 days for induction of cardiac hypertrophy. Hypertrophied animals were concurrently treated daily with aliskiren (50 mg/kg) and/or L-carnitine (200 mg/kg). Either L-carnitine or aliskiren treatment significantly reduced the elevated relative heart weight with a concomitant reduction in brain natriuretic peptide, creatine kinase-MB, and troponin T in isoproterenol treated animals. Additionally, L-carnitine and/or aliskiren treatment significantly reduced myocardial interleukin-6, lipid peroxidation, and markedly increased glutathione content. Aliskiren and/or L-carnitine treatment also attenuated myocardial fibrosis as evidenced by the significant decrease in myocardial collagen I and transforming growth factor-β1. The biochemical results were further confirmed by the improvement in myocardial histopathological architecture. Interestingly, aliskiren and L-carnitine treatment down-regulated the expression of JAK2, STAT3, and SOCS3 in hypertrophied animals. Conclusively, aliskiren/L-carnitine regimen may ameliorate cardiac hypertrophy induced by isoproterenol through mitigating oxidative stress, inflammation, and IL-6/JAK2/STAT3/SOCS3 pathway.
Keywords
JAK2/STAT3; SOCS3; Aliskiren; L-carnitine; Cardiac Hypertrophy
Statistics
Article View: 284
PDF Download: 408